IDH1 and glioma: This metabolite was recently reported as a magnetic resonance spectroscopy (MRS) marker for the noninvasive detection of 1p/19q codeleted gliomas (22) — e.g., oligodendroglioma (which, per definition, harbor IDH1 mutations).